Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
Current Opinion in HIV and AIDS
|
December 6, 2021
Fostemsavir: a first-in-class HIV-1 attachment inhibitor
Philip M Grant, Michael J Kozal
Current Opinion in HIV and AIDS
|
February 10, 2016
Tenofovir and bone health
Philip M Grant, Aoife G Cotter
Current Opinion in HIV and AIDS
|
January 6, 2010
The use of resistance testing in the management of HIV-1-infected patients
Philip M Grant, Andrew R Zolopa
Current Opinion in Investigational Drugs (London, England : 2000)
|
August 20, 2010
Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
Philip M Grant, Andrew R Zolopa
Current HIV/AIDS Reports
|
June 27, 2012
When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!
Philip M Grant, Andrew R Zolopa
BMC Medicine
|
March 18, 2014
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa
Sabina S Alistar, Philip M Grant, Eran Bendavid
Antiviral Research
|
December 31, 2013
Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations
Eugene T Richardson, Philip M Grant, Andrew R Zolopa
Drugs
|
December 18, 2015
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
Sean E Collins, Philip M Grant, Robert W Shafer
Frontiers in Immunology
|
June 2, 2020
Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells
Nancy Q Zhao, Anne-Maud Ferreira, Philip M Grant, et al.
Journal of Clinical Microbiology
|
June 25, 2014
Encephalitis caused by Chikungunya virus in a traveler from the Kingdom of Tonga
Joanna Nelson, Jesse J Waggoner, Malaya K Sahoo, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
Current Opinion in HIV and AIDS
|
December 6, 2021
Fostemsavir: a first-in-class HIV-1 attachment inhibitor
Philip M Grant, Michael J Kozal
Current Opinion in HIV and AIDS
|
February 10, 2016
Tenofovir and bone health
Philip M Grant, Aoife G Cotter
Current Opinion in HIV and AIDS
|
January 6, 2010
The use of resistance testing in the management of HIV-1-infected patients
Philip M Grant, Andrew R Zolopa
Current Opinion in Investigational Drugs (London, England : 2000)
|
August 20, 2010
Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
Philip M Grant, Andrew R Zolopa
Current HIV/AIDS Reports
|
June 27, 2012
When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!
Philip M Grant, Andrew R Zolopa
BMC Medicine
|
March 18, 2014
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa
Sabina S Alistar, Philip M Grant, Eran Bendavid
Antiviral Research
|
December 31, 2013
Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations
Eugene T Richardson, Philip M Grant, Andrew R Zolopa
Drugs
|
December 18, 2015
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
Sean E Collins, Philip M Grant, Robert W Shafer
Frontiers in Immunology
|
June 2, 2020
Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells
Nancy Q Zhao, Anne-Maud Ferreira, Philip M Grant, et al.
Journal of Clinical Microbiology
|
June 25, 2014
Encephalitis caused by Chikungunya virus in a traveler from the Kingdom of Tonga
Joanna Nelson, Jesse J Waggoner, Malaya K Sahoo, et al.
Page
of 4